Showing 1131-1140 of 1539 results for "".
- Study: Colorescience Total Eye Firm & Repair Cream Improves Appearance of Overall Periorbital Areahttps://practicaldermatology.com/news/study-colorescience-total-eye-firm-repair-cream-improves-appearance-of-overall-periorbital-area/2461316/Colorescience Total Eye Firm & Repair Cream improves periorbital wrinkles, dryness, laxity and dark circles, according to a study in the Journal of Cosmetic Dermatology. Results of the clinical study
- Senté Launches Cysteamine HSA Pigment & Tone Correctorhttps://practicaldermatology.com/news/sente-launches-cysteamine-hsa-pigment-tone-corrector/2461301/Cysteamine HSA Pigment & Tone Corrector from Senté has launched to safely and effectively target pigmentation in all skin tones. The hydroquinone-free formula is safe for long-term use and formulated for all skin types, including dry or sensitive skin.
- Expert FDA Panel Recommends Skin Lesion Analyzers and Apps for Skin Cancer Detection Keep Class III Statushttps://practicaldermatology.com/news/expert-fda-panel-recommends-skin-lesion-analyzers-and-apps-for-skin-cancer-detection-keep-class-iii-status/2461293/The FDA held a meeting with the Medical Devices Advisory Committee in late July to gather expert advice on the regulation of AI driven, skin lesion analyzers (SLAs) and Apps for skin cancer detection. Panel members urged caution for skin cancer detection SLAs and Apps and stressed the need for mo
- Lilly's Taltz Now Available in Citrate-Free Formulationhttps://practicaldermatology.com/news/lillys-taltz-now-available-in-citrate-free-formulation/2461291/Lilly's Taltz® (ixekizumab) is now available in a new, citrate-free formulation to reduce injection site pain. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formula
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib
- FDA Clears Use of Apyx Medical’s Renuvion Handpiece for Improvement in Appearance of Lax Skinhttps://practicaldermatology.com/news/fda-clears-use-of-apyx-medicals-renuvion-to-improve-appearance-of-lax-skin/2461273/The U.S. Food and Drug Administration received 510(k) clearance for the use of Apyx Medical’s Renuvion APR Handpiece for certain skin contraction procedures. Specifically, the Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aest
- Health Canada Clears Cutera’s AviClearhttps://practicaldermatology.com/news/health-canada-clears-cuteras-aviclear/2461268/Health Canada has cleared Cutera, Inc.’s AviClear for the treatment of mild, moderate, and severe acne. This Health Canada announcement comes on the heels of the U.S. Food and Drug Administration’s 510(k) clearance of AviClear, in March 2022. In addition
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- FDA Clears Soligenix's Synthetic Hypericin for Phase 2 Clinical Trial in Psoriasishttps://practicaldermatology.com/news/fda-clears-soligenixs-synthetic-hypericin-for-phase-2-clinical-trial-in-psoriasis/2461250/The U.S. Food and Drug Administration (FDA) has cleared Soligenix’s Investigational New Drug (IND) application for a Phase 2a clinical trial of topically-applied SGX302 (synthetic hypericin). Patient enrollment is slated to begin in the fourth quarter of 2022. "Duri